Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cell Death and Differentiation

• Publication date

  2011-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cdd.2011.48PMID 21546904PMCID PMC3190113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB

  2010cited by this paper
• Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells.

  2010cited by this paper
• Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression

  2010cited by this paper
• Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines

  2010cited by this paper
• CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells

  2009cited by this paper
• p21 in cancer: intricate networks and multiple activities

  2009cited by this paper
• Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells

  2009cited by this paper
• Cell cycle kinases as therapeutic targets for cancer

  2009cited by this paper
• EZH2 is essential for glioblastoma cancer stem cell maintenance.

  2009cited by this paper
• F-Box Protein FBXO31 Mediates Cyclin D1 Degradation to Induce G1 Arrest Following DNA Damage

  2009cited by this paper
• Polycomb group proteins: navigators of lineage pathways led astray in cancer

  2009cited by this paper
• Repression of E-cadherin by the polycomb group protein EZH2 in cancer

  2008cited by this paper
• Ubiquitin-independent degradation of proteins by the proteasome.

  2008cited by this paper
• G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

  2008cited by this paper
• DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy

  2008cited by this paper
• Roles of the EZH2 histone methyltransferase in cancer epigenetics.

  2008cited by this paper
• Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation*S⃞

  2008cited by this paper
• DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications.

  2008cited by this paper
• Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.

  2007cited by this paper
• Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress.

  2007cited by this paper
• The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells.

  2007cited by this paper
• Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.

  2007cited by this paper
• Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome.

  2007cited by this paper
• F-box proteins: the key to protein degradation.

  2006cited by this paper
• F-box proteins: more than baits for the SCF?

  2006cited by this paper
• Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein.

  2005cited by this paper
• The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

  2005cited by this paper
• RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.

  2005cited by this paper
• Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer*

  2005cited by this paper
• Tumour stem cells and drug resistance

  2005cited by this paper
• Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress.

  2005cited by this paper
• Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints.

  2004cited by this paper
• The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3.

  2004cited by this paper
• Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe

  2004cited by this paper
• G2 checkpoint abrogators as anticancer drugs.

  2004cited by this paper
• Targeting the checkpoint kinases: chemosensitization versus chemoprotection

  2004cited by this paper
• p21Waf1/Cip1 as a therapeutic target in breast and other cancers.

  2003cited by this paper
• EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer

  2003cited by this paper
• EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

  2003cited by this paper
• The polycomb group protein EZH2 is involved in progression of prostate cancer

  2002cited by this paper
• Targeted inactivation of p53 in human cells does not result in aneuploidy.

  2002cited by this paper
• Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage

  2002cited by this paper
• Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.

  2002cited by this paper
• Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells

  2001cited by this paper
• The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01*

  2000cited by this paper
• The DNA damage response: putting checkpoints in perspective

  2000cited by this paper
• Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination.

  2000cited by this paper
• Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

  1999cited by this paper
• Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard

  1997cited by this paper
• Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism.

  1997cited by this paper
• Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21

  1996cited by this paper

• EZH2 Dysregulation and Its Oncogenic Role in Human Cancers

  2025cites this paper
• Inhibiting EZH2 targets atypical teratoid rhabdoid tumor by triggering viral mimicry via both RNA and DNA sensing pathways

  2024cites this paper
• FBXO32-mediated degradation of PTEN promotes lung adenocarcinoma progression

  2024cites this paper
• Cellular senescence primes liver fibrosis regression through Notch‐EZH2

  2023cites this paper
• EZH2 and NF-κB: A context-dependent crosstalk and transcriptional regulation in cancer.

  2023cites this paper
• Impact of first chemotherapy exposure on follicle activation and survival in human cryopreserved ovarian tissue.

  2023cites this paper
• m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis.

  2023cites this paper
• The EZH2-H3K27me3 axis modulates aberrant transcription and apoptosis in cyclophosphamide-induced ovarian granulosa cell injury

  2023cites this paper
• Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer

  2022cites this paper
• Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress

  2022cites this paper
• Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

  2022cites this paper
• Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database

  2021cites this paper
• PRC2: an epigenetic multiprotein complex with a key role in the development of rhabdomyosarcoma carcinogenesis

  2021cites this paper
• EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells

  2021cites this paper
• The Role of Histone Lysine Methylation in the Response of Mammalian Cells to Ionizing Radiation

  2021cites this paper
• Association of genetic variants of FBXO32 and FOXO6 in the FOXO pathway with breast cancer risk

  2021cites this paper
• EZH2 inhibition sensitizes BRCA1-deficient breast cancer cells to synthetic lethal therapy with ATM inhibitors

  2021cites this paper
• Coexpression Analysis of the EZH2 Gene Using The Cancer Genome Atlas and Oncomine Databases Identifies Coexpressed Genes Involved in Biological Networks in Breast Cancer, Glioblastoma, and Prostate Cancer

  2020cites this paper
• Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation

  2020cites this paper
• Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.

  2020cites this paper
• A non-canonical EZH2 function sensitizes solid tumors to genotoxic stress

  2020cites this paper
• EZH2 has a Non-Catalytic and PRC2-Independent Role in Stabilizing DDB2 to Promote Nucleotide Excision Repair

  2020cites this paper
• Polycomb repressor complex 2 function in breast cancer (Review)

  2020cites this paper
• Genomic Instability and the Oncohistone H3K27M Drive Gliomagenesis in a Murine Model

  2020cites this paper
• miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer

  2019cites this paper
• Pharmacological inhibition of EZH2 combined with DNA-damaging agents interferes with the DNA damage response in MM cells

  2019cites this paper
• Pharmacoepigenetics of EZH2 Inhibitors

  2019cites this paper
• SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints

  2019cites this paper
• EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy

  2019cites this paper
• Alterations in epigenetic regulation contribute to neurodegeneration of ataxia-telangiectasia

  2019cites this paper
• Regulation of DNA damage-induced ATM activation by histone modifications

  2019cites this paper
• A genome-wide enrichment screen identifies NUMA1-loss as a resistance mechanism against mitotic cell-death induced by BMI1 inhibition

  2019cites this paper
• The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.

  2019cites this paper
• Inflammation-associated genomic instability in cancer

  2019cites this paper
• EZH2 promotes DNA replication by stabilizing interaction of POLδ and PCNA via methylation-mediated PCNA trimerization

  2018cites this paper
• EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression

  2018influential citation
• Targeting of Epigenetic Modifier EZH2 in Oropharyngeal Squamous Cell Carcinomas

  2018cites this paper
• 3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer.

  2018cites this paper
• eZh2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression

  2018influential citation
• EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer

  2018cites this paper
• Histone methylation in DNA repair and clinical practice: new findings during the past 5-years

  2018cites this paper
• Epigenetic therapy with inhibitors of histone methylation suppresses DNA damage signaling and increases glioma cell radiosensitivity

  2017influential citation
• Polycomb Repressor Complex 2 in Genomic Instability and Cancer

  2017cites this paper
• Epigenetic silencing and activation of transcription: influence on the radiation sensitivity of glioma cell lines

  2017cites this paper
• Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.

  2017cites this paper
• FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation

  2017cites this paper
• Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer

  2017cites this paper
• Developmental epigenetic programming of adult germ cell death disease: Polycomb protein EZH2-miR-101 pathway.

  2016cites this paper
• MiR-340 impedes the progression of laryngeal squamous cell carcinoma by targeting EZH2.

  2016cites this paper
• The Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene Expression in Human Uterine Fibroids

  2016cites this paper
• Protein breakdown in cancer cachexia.

  2016cites this paper
• Biological function and regulation of histone and non-histone lysine methylation in response to DNA damage.

  2016cites this paper
• EZH2, an on-off valve in signal network of tumor cells.

  2016cites this paper
• EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells

  2016cites this paper
• DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity

  2016cites this paper
• EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis

  2016influential citation
• Running title: ROLE OF EZH2 IN DNA DAMAGE REPAIR

  2016cites this paper
• EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells

  2016cites this paper
• Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids

  2016cites this paper
• Elevated expression of long intergenic non‐coding RNA HOTAIR in a basal‐like variant of MCF‐7 breast cancer cells

  2015cites this paper
• Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation

  2015cites this paper
• Transcriptional Response of Polycomb Group Genes to Status Epilepticus in Mice is Modified by Prior Exposure to Epileptic Preconditioning

  2015cites this paper
• Targeting EZH2 for Cancer Therapy: Progress and Perspective

  2015cites this paper
• A Fluorescent Tile DNA Diagnocode System for In Situ Rapid and Selective Diagnosis of Cytosolic RNA Cancer Markers

  2015cites this paper
• DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis

  2015cites this paper
• Targeting of cancer stem cells by inhibitors of DNA and histone methylation

  2015cites this paper
• The role of epigenomics in the neurodegeneration of ataxia-telangiectasia.

  2015cites this paper
• Transcriptional response of polycomb group genes to status epilepticus in mice is modified by prior exposure to epileptic preconditioning

  2015cites this paper
• Biology of Human Tumors VEGF / VEGFR-2 Upregulates EZH 2 Expression in Lung Adenocarcinoma Cells and EZH 2 Depletion Enhances the Response to Platinum-Based and VEGFR-2 – Targeted Therapy

  2014cites this paper
• The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)

  2014cites this paper
• Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS

  2014cites this paper
• SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression

  2014cites this paper
• VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy

  2014cites this paper
• Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells

  2014cites this paper
• EZH2: Not EZHY (Easy) to Deal

  2014cites this paper
• TP53 genomic status regulates gastric cancer cell fate decision in response to EZH2 inhibition

  2014cites this paper
• Analyse des propriétés oncogéniques de cIAP1 : contribution de ses partenaires cdc42 et E2F1

  2014cites this paper
• Chromatin modifications during repair of environmental exposure‐induced DNA damage: A potential mechanism for stable epigenetic alterations

  2014cites this paper
• CBX8, a novel DNA repair protein, promotes tumorigenesis in human esophageal carcinoma.

  2014cites this paper
• Role of EZH2 in oral squamous cell carcinoma carcinogenesis.

  2014cites this paper
• Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells

  2014cites this paper
• Title Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis( Main article )

  2013cites this paper
• Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling?

  2013cites this paper
• Polycomb repressive complex 2 contributes to DNA double-strand break repair

  2013cites this paper
• EZH 2 overexpression in natural killer / T-cell lymphoma confers growth advantage independently of histone methyltransferase activity Running Title : EZH 2 in natural killer / T-cell lymphoma

  2013cites this paper
• EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.

  2013cites this paper
• Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure

  2013cites this paper
• Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.

  2013cites this paper
• EZH2 overexpression in natural killer /T-cell lymphoma confers growth advantage independently of histone methyltransferase activity

  2013cites this paper
• EZH2: biology, disease, and structure-based drug discovery

  2013cites this paper
• EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis

  2012cites this paper
• Polycomb genes and cancer: time for clinical application?

  2012cites this paper
• Predictive Biomarkers and Personalized Medicine TP 53 GenomicStatusRegulates Sensitivity of GastricCancer Cells to the HistoneMethylation Inhibitor 3-Deazaneplanocin A ( DZNep )

  2012cites this paper
• Seeking synergy in p53 transcriptional activation for cancer therapy.

  2012cites this paper
• The dynamic interplay in chromatin remodeling factors polycomb and trithorax proteins in response to DNA damage

  2012cites this paper
• TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)

  2012cites this paper
• The emerging role of Polycomb repressors in the response to DNA damage

  2012influential citation
• The dark side of E2F1: in transit beyond apoptosis.

  2012cites this paper